Unless it's the Tooth Fairy, a "finance only" partner will uudoubtably want something in return. If the "something" is interest, it's called a loan (like GE). If the "something" is a piece of the pie, it's called a partnership (like Leo and LFB). If the "something" is stock to play with, it's called a placement (like take your pick).
(I would think "silent partner" has no place in a public company.)
What other possibilities are there? Well, there is a buyout either by another public company or a private entitity to take it all private.
Or there is a merger vis-a-vis Genzyme and BioSurface Technology.
My vote goes to the merger ... Genzyme, Pharming, Pharmathene, whoever. However, if it was my decision to make I would try for the RS instead ... to reload for more financings/dilutions until some milestones are met.
Disclosure: I am not presently a stockholder so I can be a little more objective, but I may become a stockholder again ... depending on how this all plays out. My concern at this point is that Genzyme will play Pacman and leave stockholders wondering what hit them.
Market Data 
Markets 
AI
